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ABSTRACT
Background: Depression is one of the most important causes of disability-adjusted life years. Currently, the majority of
patients are treated with SSRIs. However, the effectiveness of SSRIs is questionable. Method: The purpose of this study
was to determine the effectiveness of the pharmacotherapy treatment selective serotonin reuptake inhibitors (SSRIs) in
patients diagnosed with major depression. This was achieved by comparison to other methods of antidepressant treatment
such as, selective serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), electroconvulsive
therapy (ECT), and psychotherapy. Results: The majority of patients were taking SSRIs for treatment of depression alone
or in combination with other antidepressant medications. More than half those patients showed pharmacological
effectiveness. However, patients who were taking other types of antidepressants also experienced reduction in their
symptoms. Conclusion: The analysis of data that was collected from an outpatient mental health private practice, showed
no advantage in effectiveness of SSRIs compared with other treatment options.
Keywords: Selective serotonin reuptake inhibitors, SSRI, antidepressant, treatment of depression, selective serotonin
norepinephrine reuptake inhibitors, SNRI, tricyclic antidepressants, TCA.

INTRODUCTION
Depression is classified as a disability that impacts
the daily life of a large number of peo-ple worldwide. Specifically, “depression is the second leading
cause of life years spent with dis-ability, and the
third leading cause of disability-adjusted life
years”.[1] Between 1990 and 1998 there was a
147.5% increase in the number of patients diagnosed
with depression.[2] Data from another study showed
that between 2009-2012 at least 5% of Americans 12
years of age and older had depression.[3]
The anatomy and physiology behind depression is
known to be an imbalance of emotional homeostasis
in the limbic system, specifically between the
prefrontal cortex, cingulate cortex, and amygdala4.
The imbalance has to do mainly with serotonin, a
neurotransmitter that plays a role in “the control of
sleep and wakefulness, feeding, termoregulation,
cardiovascular function, eme-sis, sexual behavior,
spinal regulation of motor function, emotional and
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psychotic behavior, and drug-induced hallucinatory
states”.[5] Depression presents unusually low
concentration levels of serotonin in the extracellular
synapses of the brain. Although it is impossible to
measure the actu-al level of serotonin in a living
human due to the invasiveness of the procedure,
neuroimaging techniques have been used to visualize
major differences before and after treatments of
interest6.
To
counteract
this
imbalance,
antidepressant medications have been engineered to
bind to one or more of the following monoamine
transporter proteins: The serotonin transporter
(SERT), the noradrenaline transporter (NAT), and
the dopamine transporter (DAT).[1] By the
monoamine transporters binding to the medication,
there is a conformational change to inhibit the
binding
of
the
neurotransmitters.[1]
The
antidepressant medications are grouped into
categories based on which monoamine transporter
proteins they bind, such as: Tricyclic antidepressants
and related compounds, dopamine-reuptake blocking
compounds, 5-HT2 receptor antagonist properties, 5HT3 receptor antagonist properties, noradrenergic
antagonist, monoamine oxidase inhibitors, serotonin/norepinephrine reuptake inhibitors (SNRIs)
and selective serotonin reuptake inhibitors
(SSRIs).[7] Due to the high risk of side effects and
lack of effectiveness or remission however, many
patients are reluctant to take majority of
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MATERIALS AND METHODS
Fifty patients’ charts from an outpatient mental
health private practice were randomly se-lected. The
data from those charts were collected and analyzed.
Since the files come from an outpatient mental
health private practice, the patients were taking
combination therapy of phar-macotherapy and
psychotherapy. The determination of treatment
effectiveness was based upon the reduction of
symptoms and fewer side effects.

RESULTS
Thirty-four patients were female (68%) and the rest
were male (32%). The age of patients ranged from
20 to 81 years. As expected, the most common
antidepressant prescribed was SSRIs. Of the 50
patient files analyzed, a total of 88% individuals
were medicating with one or more SSRIs, 16% were
prescribed one or more SNRIs, 10% were prescribed
one or more TCAs, and 40% were prescribed one or
more of unrelated antidepressants. Such unrelated
antidepres-sants are of the following: 5HTP,
Trazodone, Wellbutrin XL, Wellbutrin XR,
Remeron, Brintel-lix, and St. Johns Wort. Along
with the antidepressant drugs being prescribed, other
medications were listed for each patient.
Medications prescribed to treat anxiety are of the
following: Vistaril, Xanax, Klonopin, Buspirone,
and Ativan. Medications prescribed that work as a
central nervous system stimulant were: Ritalin,
Concerta, Adderall XR, Provigil, Focalin, and
Focalin XR. Antipsychotic drugs prescribed to the
patients were: Abilify, Risperidone, and Seroquel.
A total of 31 patients experienced pharmacologic
effectiveness against depression with no side effects.
Of the 50 total patients, 11 were prescribed one
SSRI, and 8 of the 11 showed progress. Of the 50
total patients, 33 were prescribed a combination of
antidepressants that in-cluded at least one SSRI, and
20 showed progress.

Four patients were prescribed a single SNRI and
another 4 patients were prescribed a combination of
antidepressants including at least 1 SNRI. Of the 8
patients prescribed one or more SNRI, a total of 5
showed progress. Three of the 5 patients were
prescribed one SNRI as the antidepressant, 1 patient
took an SNRI in combination with Trazodone
(antidepressant), and 1 patient was on SNRI in
combination with Lexapro (SSRI).
Of the 5 patients prescribed one or more TCA, 4
showed progress. All 5 were taking a TCA in
combination with other antidepressants, and no
SNRIs or SSRIs.
Of the 20 patients prescribed alternative
antidepressant drugs, 14 showed progress. Nine-teen
of the patients were taking at least one antidepressant
in combination with other antidepres-sants
(including SSRIs and SNRIs), 1 of the patients was
taking an unrelated antidepressant alone. Of the 14
patients that showed progress: 1 was taking the drug
alone, 12 were taking the drug with a combination of
other antidepressants, and 1 was taking the drug in
combination with an SNRI.

DISCUSSION
The objective of this study was to determine the
overall effectiveness of selective seroto-nin reuptake
inhibitors in comparison to other methods of
treatment for depression. Of all of the patients who
were prescribed one SSRI or a combination
containing at least one SSRI, 64% showed
effectiveness. When analyzing the 64% of patient
files, 88% of the files included pa-tients who were
prescribed at least one SSRI. Of those 88%, 29% of
patients were prescribed a single SSRI and 71% of
patients were taking a combination including at least
one SSRI.
Of all of the patients who were prescribed one SNRI
or a combination containing at least one SSRI, 63%
showed effectiveness. Of those 63%, 36% of the
patients were prescribed a single SNRI, and 27% of
them were prescribed a combination containing at
least one SNRI. When comparing patients who were
taking SSRIs and SNRIs, the percentages of those
who saw pro-gress are 64% and 63%, respectively.
Patients who were taking TCA, 80% showed
progress, and all of those patients were tak-ing a
combination of antidepressants including at least one
TCA. In comparing SSRIs and TCAs, the
percentages of those who saw progress are 64% and
80%, respectively.
Seventy
percent
of
patients
prescribed
antidepressants of unrelated classifications showed
pro-gress. Five percent of the 70% were prescribed a
single antidepressant and the remaining 65% of
patients were prescribed a combination of
antidepressants, at least one from an unrelated
classifi-cation. In comparing SSRIs and unrelated
antidepressant classifications, the percentages of
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antidepressant medications and a total of 72% of
patients discontinue taking the medications by the
end of 3 months from first date prescribed.[8.,9]
This study was carried out because depression is a
serious public health concern world-wide.[10] The
number of individuals receiving antidepressant
pharmacologic treatments has in-creased. Yet,
recently there has been found a statistically
significant decrease in the rate of effec-tive
treatments.[11] Today, the leading method of
antidepressant treatment is the selective seroto-nin
reuptake inhibitors (SSRIs).[12] The purpose of this
study was to determine the effectiveness of SSRIs
compared with other antidepressant medications. In
this study, we hypothesized that SSRIs do not have
significance over the effectiveness of other methods
of antidepressant treat-ments.
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•
•
•

SSRI vs SNRI: Z-score = 0.0614, p-value = 0.95216
SSRI vs TCA: Z-score = - 0.7284, p-value = 0.4654
SSRI vs unrelated antidepressants: Z-score = 0.4968, p-value = 0.61708
All T-tests resulted in no statistical significance.
However, 88% of the total patient files observed
were prescribed one or more SSRI. Therefore, when
analyzing data there are limitations on the
conclusion of statistical significance of effectiveness
as there are not as many patients with the remaining
classifications of antidepressants. To eliminate the
limitation, an additional T-test was calculated in the
comparison of SSRIs and all other pharmacologic
methods of treatment observed. The test was twotailed and the significance level was set at 0.05. The
z-score was -0.5565 and the p-value was 0.57548.
Again, the results yielded no statistical significance.
There-fore, SSRIs are not significantly more
effective than other methods of treatment. The
details of the calculations for different groups are
written below:

CONCLUSION
The objective of this study was to determine the
overall rate of effectiveness of SSRIs in comparison
to other pharmacologic methods of antidepressant
treatments. The alternative treat-ments were SNRIs,
TCAs, and a variety of antidepressants that did not
fall into the related clas-sifications. Overall the study
showed that SSRIs do not show a higher effectivity
than other methods of antidepressant treatment.
Although the overall rate of effectiveness is 72%, the
rate could be significantly higher if SSRIs were not
the first choice of treatment. However, the data for
this study was drawn from an outpatient clinic with
mostly Caucasian ethnicity. Further stud-ies with
larger sample size, and patients with different ethnic
background is needed.
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those who saw progress are 64% and 70%,
respectively.
T-tests were completed in the comparison of SSRIs
and SNRIs, SSRIs and TCAs, and SSRIs and
unrelated antidepressant classifications. The T-tests
were two-tailed and the signifi-cance level was set at
0.05.

